Mode
Text Size
Log in / Sign up
N/A N=40 Randomized Treatment

Evaluation of Integration Success and Crestal Bone Preservation Biomet 3i's T3 Implant System

Partial Edentulism · Tooth Disease

Enrolled (actual)
40
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Cumulative Success Rate — 61; 7 implants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
T3 with DCD tapered Prevail implant (Device); Nanotite Certain tapered implant (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
ZimVie
Primary completion
Jan 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Cumulative Success Rate
61; 7
SECONDARY
Crestal Bone Changes
1.8; 3.3

Summary

This study evaluates the T3 implant system for the preservation of alveolar crestal bone and the establishment of initial integration. The new surface-treated features of the implant may contribute to improved soft and hard tissue healing. The success rate of the T3 implant will be no different than that of the control implant, which possess similar geometry but different surface treatments.

Eligibility Criteria

Inclusion Criteria

  • Patients of either sex and any race greater than 18 years of age
  • Patients for whom a decision has already been made to use dental implants for the restoration of existing edentulism in the mandible or maxilla.
  • Patients must be physically able to tolerate conventional surgical and restorative procedures.
  • Patients must agree to be evaluated for each study visit, especially the yearly follow-up visits

Exclusion Criteria

  • Patients with active infection or severe inflammation in the areas intended for implant placement.
  • Patients with a > 10 cigarette per day smoking habit.
  • Patients with uncontrolled diabetes mellitus.
  • Patients with uncontrolled metabolic bone disease where there is a diagnosis of the following: Osteomalacia, primary or secondary hyperparathyroidism, renal osteodystrophy, or Paget's disease of bone.
  • Patients with a history of therapeutic radiation to the head
  • Patients in need of bone grafting at the site of the intended study implant for augmentation purposes.
  • Patients who are known to be pregnant at the screening visit.
  • Patients with evidence of severe para-functional habits such as bruxing or clenching.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02161874). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search